Omega-3 High-Potency
An exceptional oil, an antioxidant system built to protect it, and a lipid architecture designed around what the body does with it
VivoMega® Platinum 5525 TG in triglyceride form, refined by GC Rieber in Norway and sourced through direct partnership, with natural astaxanthin and mixed tocopherols.
This is, first and foremost, an exceptional fish oil. VivoMega® Platinum 5525 TG, refined by GC Rieber in Norway and sourced through direct partnership, delivering 1,700 mg of total Omega-3 from 2,000 mg of oil, approximately 85% Omega-3 by weight, in native triglyceride form, at a TOTOX oxidation value of 3 against an industry ceiling of 26.
Concentration, chemical form, oxidative freshness, traceable source and serving size are what determine whether an Omega-3 supplement is worth taking. On every one of them, this formula sits at or near the top of what is commercially available anywhere in the world.
Specification is only half of it, because dose is a separate decision. Sourcing a premium concentrated triglyceride oil is one choice; delivering 2,000 mg of it in a daily serving is another, and it is the more expensive of the two. This is where most formulations economise: a brand can source the same grade of oil and still build a product around 1,000 mg of it, arriving at half the Omega-3 for a fraction of the raw-material cost. The specification on the front of the bottle looks identical. The serving is not.
The oil's design choices carry into where it is actually used. An EPA-forward ratio at a meaningful daily dose is not an abstraction: it is the same profile that the published literature on inflammatory joint pain, primary dysmenorrhea and the menopausal transition has been testing for years, in trials this document names and reads honestly, including where the results were not what a marketing department would have hoped for.
The oil is protected end to end by a lipid-phase antioxidant system: natural astaxanthin and mixed tocopherols, each working on a different part of the oxidation cascade. Three components. Each with a defined job. Nothing carried as a passenger.
What determines whether an Omega-3 is worth taking
"4X Absorption." "6X More Bioavailable." Compared to What?
Walk through the Omega-3 category and you will find multipliers everywhere. Four times better absorbed. Six times more bioavailable. Three times the uptake. They appear on packaging, on marketplace listings, on brand websites, always as a bare number and almost never with the sentence that would make them meaningful.
Because a multiplier is not a property of a product. It is a comparison, and the number depends entirely on what you compare against.
Choose a weak comparator and any formulation looks transformative. Compare against an unconcentrated ethyl ester oil and the gap widens. Measure in a fasted state, where absorption of any oil is poor, and it widens further. Report a single early timepoint rather than total exposure, and a difference in speed becomes a claim about amount. Each of those choices is defensible in isolation. Stacked together, they manufacture whatever multiple the marketing department requires.
The tell is always the missing denominator. Four times what? Six times which oil, in which state, measured how, over what period? A multiplier without that sentence attached is not a specification. It is a decoration.
Real quality cannot be expressed as a multiple, because it is absolute. How much Omega-3 is actually in the capsule. What chemical form it is in. How oxidised it is. How much of it you swallow in a day. Where the fish came from and how the oil was refined. Every one of those is a number that can be measured, verified against a certificate, and compared like for like against any competitor on earth.
That is the only kind of claim this document makes. We publish specifications, not multipliers, and we built a formula that can survive being read that way.
What Actually Makes an Omega-3 Oil Exceptional
Most Omega-3 marketing competes on milligrams of fish oil per capsule, which is close to meaningless on its own. A 1,000 mg fish oil capsule can contain 300 mg of Omega-3 or 850 mg. It can be in a chemical form the body handles well or poorly. It can be fresh or substantially oxidised. Five properties determine quality, and only one of them is the number on the front of most bottles.
| Property | Why it matters | This formula |
|---|---|---|
| Concentration | Determines how much Omega-3 versus filler oil you actually swallow, and how many capsules a meaningful dose requires. | ~85% Omega-3 |
| Chemical form | Triglyceride, re-esterified triglyceride and ethyl ester forms differ in how the body digests and absorbs them. | Native triglyceride |
| Oxidative state | Polyunsaturated oil degrades. Oxidised oil tastes bad, smells bad and delivers degraded fatty acids. | TOTOX 3 |
| Source and traceability | Species, waters, refining standard and chain of custody determine contaminant load and consistency. | Wild anchovy and sardine refined by GC Rieber, Norway |
| Serving size | The best oil in the world delivers nothing at a token dose. Raw-material cost scales directly with it, which is why it is the property most often quietly reduced. | 2,000 mg per serving |
This formula is strong on all five simultaneously, which is uncommon. Concentration and freshness in particular tend to trade off against each other: the more you concentrate a polyunsaturated oil, the more processing it undergoes and the more oxidative opportunity it accumulates. Achieving 85% Omega-3 at TOTOX 3 is the part of this specification that is genuinely difficult, and then delivering 2,000 mg of it is the part that is simply expensive.
Two things are worth separating here, because the industry routinely blurs them.
The fish. VivoMega is produced from wild, non-GMO, short-lived sardines and anchovies from certified fisheries, species that sit low in the food chain and live only a few years, which is why they accumulate far less mercury and persistent organic pollutants than long-lived predatory fish. The certified species include Peruvian anchoveta, jack mackerel and European sardine. The starting material is a by-product of the fishmeal industry rather than fish caught for supplement use, which is a meaningful point on both waste and stock pressure.
The refining. Concentration and purification happen in Norway, at GC Rieber's facility in Kristiansund, using a high-vacuum process designed to reduce thermal stress on the oil. This is where oxidative quality is won or lost, and it is the reason the finished concentrate carries the specification it does. The material is IFOS raw-material verified, MarinTrust chain-of-custody, Friend of the Sea certified, and produced by a GOED member manufacturer. LipoCentric sources through direct partnership rather than intermediaries, which is what makes batch-level traceability practical rather than nominal.
Concentration and Chemical Form
VivoMega® Platinum 5525 TG is specified at approximately 550 mg EPA and 250 mg DHA per gram of oil. At 2,000 mg of fish oil per daily serving, the formula is designed to deliver:
That is 1,600 mg of EPA plus DHA, with a further 100 mg of other Omega-3 fatty acids retained from the native fraction: 1,700 mg total Omega-3 from 2,000 mg of oil, or approximately 85% by weight. In two softgels.
For context on what that concentration buys: a standard 1,000 mg fish oil capsule at 30% Omega-3 delivers 300 mg. Matching this serving would take roughly eleven of them.
Why triglyceride form
Marine Omega-3 occurs naturally as triglycerides. Concentrating it commercially usually converts it to ethyl esters, and producing a concentrated triglyceride oil requires an additional re-esterification step, which is why concentrated TG oils cost meaningfully more than concentrated ethyl ester oils, and why most high-strength products on the shelf are ethyl esters whether or not they say so.
Reviews of human bioavailability generally rank the chemical forms in the order: free fatty acids, then phospholipids, then re-esterified triglycerides, then unmodified triglycerides, with ethyl esters lowest. Triglyceride form starts near the top of that hierarchy. It is also the form the body evolved to digest, which is the more durable argument.
Oxidative Integrity: The Specification That Separates Fish Oils
EPA and DHA carry five and six double bonds respectively. That is what makes them biologically active, and it is also what makes them chemically fragile. Polyunsaturated oil oxidises on exposure to oxygen, heat and light, first forming peroxides and then breaking down into secondary aldehydes and ketones.
Oxidation is measured in three numbers. Peroxide value captures primary oxidation. p-Anisidine value captures secondary breakdown products. TOTOX combines them, twice the peroxide value plus the anisidine value, into a single index of total oxidative state. GOED's voluntary monograph, the industry standard, sets the ceilings below.
| Oxidation parameter | GOED maximum | Cited VivoMega batch |
|---|---|---|
| Peroxide Value (primary oxidation) | ≤ 5 meq/kg | 0.1 |
| p-Anisidine Value (secondary oxidation) | ≤ 20 | 3 |
| TOTOX (total oxidation index) | ≤ 26 | 3 |
A peroxide value of 0.1 against a permitted 5. A TOTOX of 3 against a permitted 26. These are not marginal improvements at the edge of a specification. They are close to an order of magnitude below the limit the industry considers acceptable, and they are the single measure on which this product separates itself most decisively from everything around it.
Oxidation is not merely a sensory problem. It consumes the intact EPA and DHA you are paying for and leaves aldehydes in their place, so a heavily oxidised oil delivers less of the molecule on the label, regardless of what the label says. It is also the actual cause of the reflux and fishy aftertaste that people associate with fish oil as a category. This is why the formulation carries no enteric coating. A coating masks the symptom of oxidised oil. Fresh oil removes the cause.
The values above are raw-material batch values from the supplier certificate. Finished-product oxidative values are established separately through release and stability testing, and on-pack oxidation claims reference the finished-product release specification.
Why 2.2 : 1 EPA to DHA
This formula provides 1,100 mg EPA and 500 mg DHA per serving: 1,600 mg of combined EPA and DHA at an exact 2.2 : 1 ratio. The position is not that 2.2 : 1 is universally superior to every other ratio. It is a purposeful design choice for an adult-focused formula built around broad Omega-3 support, with a deliberate emphasis on EPA.
EPA, 1,100 mg
Incorporated into membrane lipids and serving as a precursor for distinct lipid mediators, including those involved in inflammatory resolution pathways. EPA is more readily oxidised for energy than retained structurally, which is part of why a substantial dose matters.
DHA, 500 mg
Highly enriched in neural and retinal tissue, where it contributes to the physical characteristics of membrane phospholipids, including organisation and flexibility. 500 mg sits within the range used across most DHA intervention research.
1,100 mg EPA : 500 mg DHA
| Component | Amount | Share of EPA+DHA |
|---|---|---|
| EPA | 1,100 mg | 68.75% |
| DHA | 500 mg | 31.25% |
| Total EPA+DHA | 1,600 mg | 100% |
Approximately two-thirds of the active EPA+DHA payload is EPA, while almost one-third remains DHA. EPA and DHA are both long-chain marine Omega-3 fatty acids, but they have overlapping and distinct biological roles: DHA is highly represented in neural and retinal tissue and is important for membrane structure and function, while EPA has a distinct role in lipid-mediator metabolism and can compete with arachidonic acid for pathways involved in eicosanoid production. Both fatty acids can contribute to specialised pro-resolving mediator biology.
The formulation therefore does not attempt to maximise one fatty acid at the expense of the other. It uses a substantial DHA dose while deliberately making EPA dominant, refusing the two easy extremes: a DHA-dominant formula that pushes everything toward structural membrane roles, and an EPA-only concentrate that abandons the structural side entirely.
An EPA-Forward Ratio for Active Adults
The intended adult use case includes people exposed to regular exercise, training load, recovery demands and the inflammatory stresses associated with modern lifestyles. In these settings, the formulation objective is broader than simply supplying DHA for structural or neurodevelopmental needs. EPA-forward supplementation provides a logical emphasis on the fatty-acid substrate and lipid-mediator pathways that are especially relevant to inflammatory signalling and resolution biology. This does not mean DHA is unimportant for adults: the 500 mg DHA dose is intentionally retained to preserve complementary DHA biology.
Exercise produces a normal, complex inflammatory and tissue-remodelling response. The objective of Omega-3 nutrition is not to eliminate this response, since some inflammation is necessary for adaptation. The more appropriate concept is supporting an appropriate inflammatory and resolution environment during repeated training and recovery. Human studies in trained populations show that Omega-3 supplementation can influence exercise-related inflammatory and recovery outcomes, though results vary by dose, EPA:DHA composition, duration, training status and endpoint.
A randomised trial in physically trained adults found that 715 mg per day of DHA for 12 weeks reduced delayed-onset muscle soreness at 24 and 48 hours after eccentric exercise, and altered several cytokine responses. This demonstrates that DHA itself can be relevant to recovery, and reinforces why this formula retains meaningful DHA rather than treating EPA and DHA as competitors.
The strongest positioning for this formula is therefore not that EPA is for athletes and DHA is not. It is that the formula combines substantial DHA with a deliberate EPA-forward balance for the broader demands of active adults.
What the Evidence on EPA:DHA Ratios Actually Shows
A 2026 systematic review and meta-analysis examined 96 clinical trials published before February 2025 and specifically evaluated EPA:DHA dosing ratios. The analysis found that EPA+DHA supplementation increased blood EPA:DHA ratios and reduced arachidonic acid and inflammatory markers, including CRP, TNF-α and IL-6. Ratios of 1 or higher were particularly effective for increasing the blood EPA:DHA ratio and lowering arachidonic acid, while ratios below 1 showed larger cytokine reductions in the pooled analysis. Doses of 1 to 3 grams per day were associated with the most consistent reductions in CRP, TNF-α and IL-6.
The formula supplies 1.6 g per day of EPA+DHA, which sits within the 1 to 3 g per day range identified in the 2026 meta-analysis as being associated with the most consistent reductions in CRP, TNF-α and IL-6 across clinical trials. The formula does not rely on a high total oil quantity to communicate strength: the relevant nutritional payload is the actual EPA+DHA, 1,600 mg of named Omega-3 fatty acids, with EPA intentionally carrying the larger share.
Khabir Z, et al. Role of the EPA:DHA dosing ratio in Omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. 2026;66(20):3866–3887.
Inflammation, Immunity and the DHA Question
EPA and DHA influence immune-cell membranes, lipid-mediator pathways and cytokine signalling. EPA can alter the balance of mediators derived from arachidonic acid, while both EPA and DHA can contribute to specialised pro-resolving mediator pathways. This makes an EPA-forward ratio biologically relevant to a product positioned around healthy inflammatory balance. It does not make the product a treatment for autoimmune disease: clinical evidence in rheumatoid arthritis is mixed, and the certainty of evidence for several outcomes is low. The language used here is deliberately "supports healthy inflammatory balance," not "treats autoimmune inflammation."
None of this makes DHA a secondary nutrient. DHA is important throughout life, not only for pregnant women and children, and its established structural roles in neural and retinal tissue make DHA-rich formulations particularly relevant when neurodevelopmental or neural and visual structural needs are the primary formulation objective. The difference here is a different design objective: adult daily Omega-3 support with an intentional EPA emphasis, not a claim that DHA is less valuable.
More EPA
Greater emphasis on inflammatory and lipid-mediator balance.
Meaningful DHA
Retention of DHA-dependent membrane, neural, retinal and pro-resolving functions.
Both together
A broader adult Omega-3 profile, rather than a single-function approach.
Rondanelli M, et al. Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis disease activity indicators: systematic review and meta-analysis of randomized placebo-controlled trials. 2022.
Every Ingredient Has a Job
Three components. Each answers a specific question about the formulation, and each would be removed if it did not.
| Component | Per serving | The job it does |
|---|---|---|
| VivoMega® Platinum 5525 TG | 2,000 mg | Delivers the entire Omega-3 payload at 85% concentration in native triglyceride form. This is the product; everything else exists to protect it. |
| Natural astaxanthin | 2 mg | Lipid-phase antioxidant defending the oil against oxidative degradation through shelf life. Astaxanthin's extended conjugated structure lets it work across the lipid membrane rather than only at its surface. |
| Natural mixed tocopherols | 3 mg | Chain-breaking antioxidant covering a different part of the oxidation cascade from astaxanthin. The two are complementary rather than redundant: one intercepts radicals, the other extends protection through the lipid phase. |
The antioxidant system, specifically
An oil this concentrated and this fresh is worth defending, and freshness at the point of manufacture means nothing if it degrades before the bottle is finished. Astaxanthin and tocopherols are not present as marketing actives: at 2 mg and 3 mg they are not dosed to make systemic claims, and we do not make any. They are there to keep a TOTOX of 3 looking like a TOTOX of 3 at the end of shelf life, which is the only antioxidant claim that matters in a fish oil.
No enteric coating, because fresh oil does not need one. No added phospholipid, no filler oils padding the softgel. No botanical extracts, no nootropic layer, no second bottle. Nothing was added to lengthen the ingredient list, and nothing is in the formula that cannot answer the question of what job it does.
The same formula, read against the trials that have actually tested it in women
Inflammatory Load, Across Life Stages
Joint pain, stiffness and a general inflammatory load are not confined to a diagnosed condition. They show up after childbirth, after a decade at a desk, after forty, and in the ordinary wear of an active life. The clinical literature on Omega-3 and inflammatory pain is older and better established than almost anything else in this document, and it long predates any recent interest in the topic.
Pooling seventeen randomised controlled trials in rheumatoid arthritis, inflammatory bowel disease and dysmenorrhea, this analysis found that omega-3 supplementation over three to four months reduced patient-reported pain intensity, cut morning stiffness by nearly half an hour, reduced the number of painful or tender joints, and lowered the amount of NSAID medication participants needed. The effect on physician-assessed pain did not reach significance, which the document reports rather than omits.
A 2022 meta-analysis focused specifically on rheumatoid arthritis reinforces the same pattern for autoimmune joint inflammation, though it is also honest that the certainty of evidence for several individual outcomes remains low, as noted in Section 08.
None of this is a new claim layered onto the formula for a new audience. It is the intended use of the same EPA-forward ratio that Part I built this formula around, read against the specific condition where omega-3's inflammatory-pain evidence happens to be oldest and most consistent.
Period Pain: What the Trials Show
Primary dysmenorrhea, menstrual cramping with no underlying pelvic disease, is one of the most common recurring pain conditions in women, and it has its own dedicated body of omega-3 trial evidence, separate from the general inflammatory-pain literature above.
Pooling the available randomised trials, this analysis found that omega-3 significantly reduced the severity of primary dysmenorrhea. An earlier randomised trial in adolescents found the same direction of effect: two months of fish oil brought the standard Cox Menstrual Symptom Scale down from a baseline of 69.9 to 44.0, a highly significant reduction. A later trial found omega-3 alone, and omega-3 combined with vitamin E, both outperformed placebo on menstrual pain.
One honest caveat belongs here, because leaving it out would misrepresent the research this section relies on. The 2022 meta-regression found that lower daily intakes of omega-3 were associated with larger reductions in dysmenorrhea severity, and that effectiveness diminished with age. This document does not claim that this formula's 1,700 mg total Omega-3 dose was set to optimise for period pain specifically: the dose was set by the oil-quality and general Omega-3 status objectives covered in Part I. What the evidence supports is narrower and still genuine: omega-3 as a class, at doses this formula's EPA and DHA content sits comfortably within, has real randomised-trial support for this specific symptom.
Perimenopause and Menopause: An Honest Picture
This is where the temptation to overclaim is strongest, and where the evidence is least willing to cooperate. The document's claim discipline applies here more than anywhere else in it.
This document is not going to claim that omega-3 relieves menopause symptoms, because the trials that tested that specific claim did not find it. What it will say instead rests on different, more defensible ground.
DHA, the fatty acid this formula supplies at 500 mg per serving, is disproportionately concentrated in brain tissue relative to almost anywhere else in the body. The menopausal transition is a period of declining and erratic estrogen availability in the brain, coinciding with disrupted sleep, transient cognitive change and shifts in mood and anxiety. A 2025 narrative review describes the menopausal transition as "a critical window of intervention opportunity" for EPA and DHA, while stating plainly that randomised trial evidence for this specific window is still sparse and that preclinical and epidemiological work is running ahead of confirmed clinical results.
The distinction this section holds onto: DHA has an established, structural reason to matter during this transition, and this formula supplies a dose within the range that DHA-and-brain research has actually used. That is a different, smaller claim than symptom relief, and it is the one the evidence currently supports.
What the formula supports, and where it sits in the wider architecture
Formula Architecture
The complete formula, as it appears per daily serving of two softgels.
| Component | Per daily serving | Role |
|---|---|---|
| VivoMega® Platinum 5525 TG | 2,000 mg | Concentrated triglyceride Omega-3 at TOTOX 3 |
| — Total Omega-3 (as triglycerides) | 1,700 mg | Principal Omega-3 payload, ~85% of oil weight |
| — EPA | 1,100 mg | Signalling and lipid-mediator oriented |
| — DHA | 500 mg | Structurally oriented |
| — Other Omega-3 | 100 mg | Retained native fraction |
| Natural astaxanthin | 2 mg | Lipid-phase antioxidant protection |
| Natural mixed tocopherols | 3 mg | Complementary antioxidant protection |
An exceptional payload, protected. The oil carries the product. The antioxidant system defends it through shelf life. One bottle, two softgels, taken with a meal.
What This Formula Is Designed to Support
The scientific rationale points toward four physiological domains. These are support objectives grounded in the established biology of EPA, DHA and membrane lipids, not disease-treatment claims.
Membrane and cellular structure
EPA and DHA are incorporated into membrane glycerophospholipids, where fatty-acid composition influences membrane organisation, fluidity and the behaviour of membrane-associated proteins. A substantial daily dose of both is what makes participation in those pools possible.
Lipid signalling
EPA and DHA are precursors for distinct families of bioactive lipid mediators, including those involved in the resolution phase of inflammatory signalling. This is where the EPA-forward ratio does its work.
Neurocellular biology
DHA is the dominant long-chain Omega-3 in neural and retinal membranes, where it contributes to the physical properties of the phospholipid bilayer. 500 mg per serving is a dose consistent with the intervention literature.
Cardiovascular physiology
EPA and DHA have established physiological relevance to lipid metabolism and cardiovascular biology, and this is the domain with the largest body of human outcome research behind it, though effects depend on dose, population and formulation.
Notice that all four domains are downstream of the same requirement: enough EPA and DHA, in good condition, reaching circulation. That is why the formulation invests where it does: in concentration, in freshness, and in dose.
The LipoCentric Protocol
Omega-3 High-Potency is designed as a foundational lipid layer. Other LipoCentric formulations pair with it where they address a different biological layer: the objective is complementary architecture, not stacking products for their own sake.
Neurocellular Foundation
Omega-3 supplies the structural membrane lipid layer; Magnesium Evolution provides the complementary magnesium-dependent cellular and neurophysiological layer.
Cardiometabolic Architecture
Omega-3 addresses lipid biology while Berberine Evolution is formulated around metabolic regulation. The mechanisms are complementary rather than duplicative.
Metabolic and Membrane
Three distinct layers: membrane lipid biology, magnesium-dependent cellular processes, and metabolic regulation.
Skin and Structural Support
Omega-3 contributes the lipid and membrane layer; Japanese Targeted Collagen addresses extracellular matrix homeostasis.
Muscle Preservation
Omega-3 supplies the lipid layer while essential amino acids and HMB address the amino-acid substrate and proteostasis layers.
Gut and Metabolic
Probiotic Evolution addresses the microbiome layer, Berberine Evolution the metabolic layer, and Omega-3 the systemic lipid layer.
What We Say With Confidence
Everything below is stated without hedging, because every item is either a measured specification or established physiology.
| We say | On the basis of |
|---|---|
| 2,000 mg of concentrated fish oil per daily serving, delivering 1,700 mg total Omega-3, approximately 85% Omega-3 by weight. | Measured · certificate and finished-product testing |
| 1,100 mg EPA and 500 mg DHA, a 2.2 : 1 ratio supplying a substantial individual dose of each. | Measured |
| Native triglyceride form, the form marine Omega-3 naturally occurs in and the form the body evolved to digest. | Measured · specification |
| TOTOX of 3 against a GOED ceiling of 26, with peroxide value at 0.1 against a permitted 5. | Measured · batch certificate |
| Wild, short-lived anchovy and sardine from certified fisheries, refined in Norway by GC Rieber, IFOS raw-material verified and MarinTrust chain-of-custody. | Verified · certification |
| An antioxidant system of natural astaxanthin and mixed tocopherols protecting the oil through shelf life. | Formulation · stability tested |
| EPA and DHA are incorporated into membrane phospholipids and serve as precursors for bioactive lipid mediators. | Established physiology |
| Dietary lipids are digested, absorbed, re-esterified and packaged into lipoprotein particles for export through lymphatic transport. | Established physiology |
| A meta-analysis of 17 human randomised trials found omega-3 supplementation reduces inflammatory joint pain, morning stiffness and NSAID use. | Meta-analysis of 17 human RCTs |
| A systematic review and meta-analysis found omega-3 significantly reduces the severity of primary dysmenorrhea. | Meta-analysis of human RCTs |
This is a formula that can be read line by line by anyone. Every quality claim is a number on a certificate. Every biological claim names the tier of evidence it rests on. There is no multiplier anywhere in this document, because there is nothing here that requires one.
Selected Scientific References
- GC Rieber VivoMega. VivoMega® Platinum 5525 TG Premium specification; sourcing and sustainability documentation. GC Rieber VivoMega.
- GOED. GOED Voluntary Monograph. Oxidation specifications: PV ≤ 5 meq/kg, p-anisidine ≤ 20, TOTOX ≤ 26. GOED.
- NIH Office of Dietary Supplements. Omega-3 Fatty Acids — Health Professional Fact Sheet. NIH ODS.
- Bioavailability of EPA and DHA in humans — a comprehensive review. 2024. PubMed.
- Harris WS et al. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Marine Drugs. 2012. PubMed.
- Khabir Z, et al. Role of the EPA:DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. 2026;66(20):3866–3887. DOI.
- Macartney MJ, et al. Microencapsulated docosahexaenoic acid increases the Omega-3 Index and attenuates the physiological impact of eccentric exercise in physically trained adults: a 12-week double-blind placebo-controlled trial. European Journal of Nutrition. 2026.
- Rondanelli M, et al. Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis disease activity indicators: systematic review and meta-analysis of randomized placebo-controlled trials. 2022.
- Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1-2):210–223. DOI.
- Mohammadi MM, Mirjalili R, Faraji A. The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. 2022;78(5):721–731. DOI.
- Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. American Journal of Obstetrics and Gynecology. 1996;174(4):1335–1338. DOI.
- Sadeghi N, Paknezhad F, Rashidi Nooshabadi M, Kavianpour M, Jafari Rad S, Khadem Haghighian H. Vitamin E and fish oil, separately or in combination, on treatment of primary dysmenorrhea: a double-blind, randomized clinical trial. Gynecological Endocrinology. 2018;34(9):804–808. DOI.
- Mohammady M, Janani L, Jahanfar S, Mousavi MS. Effect of omega-3 supplements on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2018;228:295–302. DOI.
- Cohen LS, Joffe H, Guthrie KA, et al. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause. 2014;21(4):347–354. DOI.
- Minihane AM. Omega-3 fatty acids, brain health and the menopause. Post Reproductive Health. 2025;31(2):97–104. DOI.
Human and mechanistic literature identified through PubMed. Readers are directed to the primary sources for full methods and limitations.
Science. Transparency. Well-being.